Krystal Biotech Inc (KRYS)
Solvency ratios
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.07 | 1.05 | 1.05 | 1.05 | 1.09 | 1.07 | 1.07 | 1.08 | 1.12 | 1.06 | 1.10 | 1.06 | 1.03 | 1.06 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 |
Krystal Biotech Inc's solvency ratios, including the debt-to-assets ratio, debt-to-capital ratio, debt-to-equity ratio, and financial leverage ratio, have remained stable at 0.00 for the debt-related ratios, indicating that the company has not used debt to finance its operations. However, the financial leverage ratio has fluctuated over the periods, ranging from 1.03 to 1.12, showing variability in the company's leverage position.
The lack of debt in the capital structure is a positive sign for Krystal Biotech Inc, as it indicates lower financial risk and potential for financial stability. The fluctuation in the financial leverage ratio suggests changes in the company's capital structure and how assets are financed, which may require further analysis to understand the underlying reasons behind these fluctuations.
Overall, the consistent low debt ratios and the varying financial leverage ratio indicate that Krystal Biotech Inc has been managing its solvency effectively, but continuous monitoring and analysis are necessary to ensure the company maintains a healthy financial position in the long term.
Coverage ratios
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -2.70 | -2.19 | -5.91 | -6.12 | -5.75 | — | — | — | — | -45.76 | -38.08 | -34.08 | -27.75 | — | — | — | -43.05 | -19.63 | -14.08 | -10.56 |
The interest coverage ratio for Krystal Biotech Inc over the past several quarters has shown significant fluctuations. The ratio indicates the company's ability to cover its interest expenses with its operating income.
The negative values observed in the interest coverage ratio for most periods suggest that the company's operating income was insufficient to cover its interest expenses during those quarters. This raises concerns about the company's financial health and its ability to meet its debt obligations.
The trend of declining interest coverage ratios from around -2.19 to -6.12 over the latest quarters indicates a worsening financial situation in terms of its ability to meet interest payments. The notable spike in the ratio to -45.76 in the Dec 31, 2021 quarter indicates an extreme decline in the company's ability to cover interest expenses with operating income.
Overall, the consistently negative interest coverage ratios and the substantial fluctuations highlight a risky financial position for Krystal Biotech Inc, signaling potential difficulties in managing its debt obligations and sustaining future operations. Further analysis of the company's financial performance and debt management strategies would be necessary to address these concerns.